China (Mainland)
2-Formyl-3-oxo-propanoic acid ethyl ester CAS NO.80370-42-9
- Min.Order: 0
- Payment Terms:
- Product Details
Keywords
- Contact us
- 2-Formyl-3-oxo-propanoic acid ethyl ester manufacturers
Quick Details
- ProName: 2-Formyl-3-oxo-propanoic acid ethyl es...
- CasNo: 80370-42-9
- Appearance: See the description
- Application: Pharmaceutical intermediates
- PackAge: According to your requirements
- Port: changzhou ,shanghai ,shenzhen
- Purity: 97%（GC）
- Storage: dry
- Transportation: air or sea
- LimitNum: 0
Superiority
Contact us
Details
Changzhou Forest-Pharm Co., Ltd is private-owned company which is established in 2129. We are working on process R&D, manufacture and trade of advanced pharmaceutical intermediates and APIs.
Our main products are Nizatidine, Famotidine, Benzydamine HCL a relative intermediates. The plant is located in Binhai, Yancheng, which is in compliance with cGMP guidance and is certified by ISO9001:2008 and ISO14001:2004, OHSAS18001:2007.
We have built our own R&D center and Kilo-grade laboratory, which is locates in Changzhou. we are focusing on manufacturing of tyrosine kinase inhibitor (such as Lapatinib, Dasatinib, Bosutinib, Tofacitinib, Ibrutinib, Ceritinib, Afatinib, Lenvatinb, Osimertinib, neratinib) and relative pharmaceutical intermediates, etc. Also some other new drugs with good clinic reputation such as Niraparib and Ritonavir also are under bench investigation.
Our main products are Nizatidine, Famotidine, Benzydamine HCL a relative intermediates. The plant is located in Binhai, Yancheng, which is in compliance with cGMP guidance and is certified by ISO9001:2008 and ISO14001:2004, OHSAS18001:2007.
We have built our own R&D center and Kilo-grade laboratory, which is locates in Changzhou. we are focusing on manufacturing of tyrosine kinase inhibitor (such as Lapatinib, Dasatinib, Bosutinib, Tofacitinib, Ibrutinib, Ceritinib, Afatinib, Lenvatinb, Osimertinib, neratinib) and relative pharmaceutical intermediates, etc. Also some other new drugs with good clinic reputation such as Niraparib and Ritonavir also are under bench investigation.
![2-(4-Aminophenyl)-6-tert-butyl-1H-pyrazolo[1,5-b][1,2,4]triazole](http://file1.lookchem.com/cas/reactions/2021/07/02/24023908.png)
